找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Nanomedicines for Effective Cancer Therapy; Hitoshi Kasai,Hiroshi Uji-i,Johan Hofkens Book 2024 The Editor(s) (if applicable) and The Auth

[復(fù)制鏈接]
樓主: Forestall
31#
發(fā)表于 2025-3-26 23:09:01 | 只看該作者
Targeted Drug Delivery for Cancer Therapy Using Functionalized Nanocarrierse therapies are based on passive accumulation in tumor tissues via enhanced permeability of tumor vasculature, namely the enhanced permeability and retention effect (EPR effect). However, the efficacy of EPR-based drug delivery is controversial because liposomal doxorubicin potentially has an insuf
32#
發(fā)表于 2025-3-27 02:24:08 | 只看該作者
Cancer Photo Therapies that Target Mitochondriapeutic molecule of choice to act where it is needed and for the required time. Cancer photo therapy typically involves photochemical reactions induced by light irradiation to cause cell death. Over the past few decades, mitochondria have attracted considerable attention in the field of therapy. The
33#
發(fā)表于 2025-3-27 05:54:26 | 只看該作者
34#
發(fā)表于 2025-3-27 12:23:45 | 只看該作者
35#
發(fā)表于 2025-3-27 13:43:27 | 只看該作者
36#
發(fā)表于 2025-3-27 19:25:00 | 只看該作者
Cell Membrane Mimetic Amphiphilic Phospholipid Polymers for Advanced Nanomedicinee, we introduce phospholipid polymers, whose molecular design is based on the surface structure of cell membranes, and their role in drug formulation. These phospholipid polymers are amphiphilic, can substantially enhance the solubility of drugs in aqueous media, and can permeate membranes through m
37#
發(fā)表于 2025-3-27 23:17:52 | 只看該作者
38#
發(fā)表于 2025-3-28 04:45:33 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:50 | 只看該作者
3D Tumor Models—Nanomedicine in the Third Dimensionnced efficacy and reduced side effects has marked a significant step forward in cancer research. However, the promising results observed in preclinical studies show low translatability into the clinic, due to a lack of adequate preclinical models that faithfully mimic the complex tumor microenvironm
40#
發(fā)表于 2025-3-28 11:55:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 14:26
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
和顺县| 桃源县| 开阳县| 鄱阳县| 尉犁县| 达州市| 南昌市| 中西区| 井冈山市| 迭部县| 南召县| 同德县| 常山县| 勐海县| 定襄县| 新津县| 珲春市| 陆川县| 南郑县| 新晃| 浮梁县| 岳池县| 从化市| 台江县| 奎屯市| 永登县| 察哈| 新河县| 达拉特旗| 射洪县| 越西县| 楚雄市| 阳西县| 盐边县| 武平县| 萍乡市| 密云县| 旅游| 手机| 汉沽区| 蓬溪县|